Interleukin-4 (IL-4) is a major cytokine regulating IgE production and IgE response. Neuroendocrine growth factors, such as growth hormone and insulin-like growth factor (IGF-1), also modulate IgE production by human B cells. We report that in both human primary immune cells and established B cell lines, IGF-1 increased expression of the IL-4-induced type II IgE receptor (FcεRII/CD23). This effect was also seen at the mRNA level. IGF-1 increased the activity of signal transducer and activator of transcription 6 (STAT6) in response to IL-4, and activated NF-κB. STAT6 and NF-κB are major transcription factors controlling CD23 expression. The tyrosine kinase inhibitor, tyrphostin, abolished both IL-4- and IL-4 plus IGF-1-mediated induction of STAT6 and the subsequent CD23 expression. In contrast, pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, only suppressed the enhancing effect of IGF-1 on IL-4-induced CD23 expression. Our data suggest that IGF-1 modulates CD23 gene expression by affecting the STAT6 and NF-κB pathways. Regulation of CD23 by IGF-1 may have an important implication for the immunomodulatory potential of IGF-1, and may provide a new therapeutic target for allergy and other hypersensitivity reactions involving an excessive IgE response.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: